Literature DB >> 31839374

Overcoming the Brain Barriers: From Immune Cells to Nanoparticles.

Marc Charabati1, Jean-Michel Rabanel2, Charles Ramassamy3, Alexandre Prat4.   

Abstract

Nanoparticulate carriers, often referred to as nanoparticles (NPs), represent an important pharmacological advance for drug protection and tissue-specific drug delivery. Accessing the central nervous system (CNS), however, is a complex process regulated by mainly three brain barriers. While some leukocyte (i.e., immune cell) subsets are equipped with the adequate molecular machinery to infiltrate the CNS in physiological and/or pathological contexts, the successful delivery of NPs into the CNS remains hindered by the tightness of the brain barriers. Here, we present an overview of the three major brain barriers and the mechanisms allowing leukocytes to migrate across each of them. We subsequently review different immune-inspired and -mediated strategies to deliver NPs into the CNS. Finally, we discuss the prospect of exploiting leukocyte trafficking mechanisms for further progress. Crown
Copyright © 2019. Published by Elsevier Ltd. All rights reserved.

Keywords:  CNS drug delivery; blood–brain barrier; blood–cerebrospinal barrier; blood–leptomeningeal barrier; immune cell migration; leukocyte migration

Mesh:

Year:  2019        PMID: 31839374     DOI: 10.1016/j.tips.2019.11.001

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN: 0165-6147            Impact factor:   14.819


  7 in total

Review 1.  Targeting neuroinflammation by intranasal delivery of nanoparticles in neurological diseases: a comprehensive review.

Authors:  Fatemeh Moradi; Nasrin Dashti
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2022-01-04       Impact factor: 3.000

Review 2.  Improving Drug Delivery for Alzheimer's Disease Through Nose-to-Brain Delivery Using Nanoemulsions, Nanostructured Lipid Carriers (NLC) and in situ Hydrogels.

Authors:  Sara Cunha; Ben Forbes; José Manuel Sousa Lobo; Ana Catarina Silva
Journal:  Int J Nanomedicine       Date:  2021-06-29

Review 3.  Neuroinflammatory Mechanisms of Mitochondrial Dysfunction and Neurodegeneration in Glaucoma.

Authors:  Joao N Duarte
Journal:  J Ophthalmol       Date:  2021-04-15       Impact factor: 1.909

4.  A stepwise-targeting strategy for the treatment of cerebral ischemic stroke.

Authors:  Jingbo Hu; Xueying Tan; Dongwei Wang; Yixuan Li; Hongze Liang; Jiejun Peng; Fengyan Li; Quan Zhou; Peiwu Geng; Shuanghu Wang; Yue Yu; Jin Liu
Journal:  J Nanobiotechnology       Date:  2021-11-17       Impact factor: 9.429

Review 5.  Spatial and temporal variation of routine parameters: pitfalls in the cerebrospinal fluid analysis in central nervous system infections.

Authors:  Marija Djukic; Peter Lange; Frank Erbguth; Roland Nau
Journal:  J Neuroinflammation       Date:  2022-07-06       Impact factor: 9.587

Review 6.  siRNA-based nanotherapeutics as emerging modalities for immune-mediated diseases: A preliminary review.

Authors:  Saman Sargazi; Rabia Arshad; Reza Ghamari; Abbas Rahdar; Ali Bakhshi; Sonia Fathi Karkan; Narges Ajalli; Muhammad Bilal; Ana M Díez-Pascual
Journal:  Cell Biol Int       Date:  2022-07-13       Impact factor: 4.473

Review 7.  Neuroinflammation Treatment via Targeted Delivery of Nanoparticles.

Authors:  Susana R Cerqueira; Nagi G Ayad; Jae K Lee
Journal:  Front Cell Neurosci       Date:  2020-09-30       Impact factor: 5.505

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.